You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Histological Features Associated With Vemurafenib-Induced Skin Toxicities: Examination of 141 Cutaneous Lesions Biopsied During Therapy

Curry, Jonathan L. MD*,†; Tetzlaff, Michael T. MD, PhD*; Nicholson, Kimberly MD; Duvic, Madeleine MD; Kim, Kevin B. MD§; Tsai, Kenneth Y. MD, PhD; Hwu, Wen-Jen MD, PhD§; Hong, David S. MD; Prieto, Victor G. MD, PhD*,†; Torres-Cabala, Carlos A. MD*,†

American Journal of Dermatopathology:
doi: 10.1097/DAD.0000000000000018
Original Study
Abstract

Abstract: Dermatologic toxicities (DTs) associated with vemurafenib therapy include actinic keratosis (AK), verruca vulgaris (VV), keratoacanthoma (KA), and invasive squamous cell carcinoma (SCC), which may share histological features. The authors report the histological features to aid in distinguishing among these DTs. A 3-year retrospective examination of the authors' surgical pathology database was conducted and 141 cases of vemurafenib-associated DTs from 33 patients were identified. DTs were categorized into 3 groups: (1) cutaneous epithelial proliferations (CEP), (2) melanocytic lesions, and (3) inflammatory dermatoses. The authors compared the groups using analysis of variance, and P < 0.05 was considered significant. CEP (n = 120) accounted for 85% of all DTs biopsied. The most frequent diagnosis in the CEP category was VV (40%), followed by invasive SCC (24%) and AK (21%). KA was diagnosed in 3% of CEP. Histologically, AK, VV, KA, and invasive SCC may demonstrate similar morphological features in superficial sampled specimens. The mitotic rate was significantly higher in invasive SCC than other CEP (P < 0.003). The median tumor thickness of SCC was 2.60 mm. Evaluating the base of the keratinized lesion will aid in distinguishing the histological type of CEP and the management of the DTs; thus, a deep shave or punch biopsy may be warranted for patients who received vemurafenib therapy.

Author Information

Departments of *Pathology,

Dermatology, and

Atlanta Dermatopathology, Atlanta, GA; and

§Melanoma Medical Oncology, and

Investigative Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX.

Reprints: Jonathan L. Curry, MD, Department of Pathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 (e-mail: jlcurry@mdanderson.org).

K. B. Kim serves on the advisory Board for Roche/Genentech. The remaining authors declare no other conflicts of interest.

© 2014 by Lippincott Williams & Wilkins.